Novavax aims for 2 billion Covid-19 vaccine doses with expanded India deal

16-Sep-2020

US drug developer Novavax Inc said on Tuesday it was doubling its potential Covid-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, sending its shares up about 7 per cent. In August, Novavax signed a deal with Serum Institute, the world�s largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India. As part of the expanded agreement, Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVXCoV2373, which Novavax said will bring its manufacturing capacity to over two billion doses by mid-2021.